LLPC Associated studies

Open studies

Short name	BOB1 TCR T
Study title	BOB1-TCR therapy for treatment of relapsed or refractory B cell malignancies - A Phase 1/2 clinical trial
Status	Open in LUMC (Peter van Balen)
Population	R/R NHL, R/R ALL, R/R MM
Study docs	Study synopsis

Short name	Terzo
Study title	A multicentre open-label Phase 3, randomised controlled trial of duvelisib versus investigator’s choice of gemcitabine or bendamustine in patients with relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype (TERZO)
Status	Open in ErasmusMC, LUMC en Amsterdam UMC
Medication	Duvelisib vs investigator’s choice (Gemcitabine of Bendamustine)
Population	Relapsed/refractory nodaal T-cel lymfoom met T follicular helper (TFH) fenotype na ≥1 eerdere lijn therapie
Study docs	In en exclusiecriteria

Short name	GOLSEEK-4
Study title	A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma
Status	open in AUMC, UMCU en UMCG
Population	Recurrent follicular lymphoma after at least one prior line of treatment with an anti-CD20 agent and an alkylating agent (e.g., cyclophosphamide, bendamustine). Note: there must be no evidence of prior transformation.
Study docs	In- en exclusiecriteria

Short name	CARMAN
Study title	Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)
Status	Open in: - Erasmus MC (Doorduijn), - Amsterdam UMC (Kersten), - UMCG (v Meerten)
Population	previously untreated MCL, high risk. At least one High risk MCL feature, defined as I. MIPI-c high intermediate (HI) or high (H) risk (i.e. high-risk MIPI irrespective of Ki-67 or intermediate risk MIPI and Ki-67>=30% (Ki-67 based on local pathology) and/or II. TP53 deletion and /or mutation and/or TP53 overexpression by immunohistochemistry (> 50% of lymphoma cells), sequencing (mutations and deletions) or FISH
Study docs	In- en exclusiecriteria

Short name	Athena-1 (Regeneron)
Study title	A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 X anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination with Odronextamab, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, in Patients with Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)
Status	Open in Erasmus MC and Amsterdam UMC
Medication	Odronextamab combined with REGN5837
Population	Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (DLBCL) after two lines including CAR T-cell therapy
Study docs	In and exclusion criteria

Short name	CA1231000
Study title	A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination with Anti-lymphoma Agents in Participants with Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
Status	Open in MUMC (marjolein.vander.poel@mumc.nl) and in UMCG (m.nijland@umcg.nl)
Medication	BMS-986458; BCl6 degrader
Population	relapsed/refractory DLBCL and FL
study docs	In- and exclusion criteria

Short name	KT-US-499-0150
Study title	A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
Status	Current phase 1 a/b cohorten zijn open; Expansie Cohort C: voor frontline LBCL - Dose Level 3: 2.0 x 105 KITE-753 CAR+ T cells/kg Expansie Cohort D: voor R/R MCL - Dose Level 3: 2.0 x 105 KITE-753 CAR+ T cells/kg Current phase 2 cohort is open; R/R LBCL na tenminste 2 eerdere systemische behandellijnen Dose Level 3: 2.0 x 105 KITE-753 CAR+ T cells/kg Open in Amsterdam UMC, location VUMC (m.j.kersten@amsterdamumc.nl, ilse.kuipers@amsterdamumc.nl, trialbureaulymfoid@amsterdamumc.nl)
Medication	KITE-363 & KITE-753; Autologous anti-CD19/CD20 chimeric antigen receptor [CAR] T-cell product
Population	Relapsed and/or Refractory B-cell Lymphoma
Study info	Study information Study Schema
Study docs	In- and exclusion criteria

Short name	NX-5948-301
Study title	A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Status	open in ErasmusMC (j.doorduijn@erasmusmc.nl) and RadboudUMC (W. Stevens), UMCU (Utrecht) (A. Pulles), UMCG (Groningen) (M.Nijland)
Medication	BTK-degrader (oral)
Population	R/R CLL/SLL with CNS involvement
Study Docs	In- en exclusiecriteria Advertentie text (approved by EC)

Atalanta-1 (CP0201-NHL)

ZUMA 23

CD19/CD20 biCAR

BYON4228

OLYMPIA-4

Magnaz

M22-132

GCT3014-01

R/R CLL (GCT3013-03)

DALY 2-EU

EPCORE NHL-2

ZUMA-2 cohort

GEN3009

Valentine study

Lym1002

EDO-S101-1001

TRANSCEND WORLD (Celgene JCAR017-BCM-001)

CDK9

ACT15320

BELINDA (CCTL019H2301)

TRANSFORM (Celgene JCAR017-BCM-003

Harbour